McGill University AIDS Centre, Lady Davis Institute, Jewish General Hospital, Montreal, Québec, Canada.
J Virol. 2013 Sep;87(17):9620-32. doi: 10.1128/JVI.01165-13. Epub 2013 Jun 26.
The HIV-1 latent reservoir represents an important source of genetic diversity that could contribute to viral evolution and multidrug resistance following latent virus reactivation. This could occur by superinfection of a latently infected cell. We asked whether latent viruses might be reactivated when their host cells are superinfected, and if so, whether they could contribute to the generation of recombinant viruses. Using populations of latently infected Jurkat cells, we found that latent viruses were efficiently reactivated upon superinfection. Pathways leading to latent virus reactivation via superinfection might include gp120-CD4/CXCR4-induced signaling, modulation of the cellular environment by Nef, and/or the activity of Tat produced upon superinfection. Using a range of antiviral compounds and genetic approaches, we show that gp120 and Nef are not required for latent virus reactivation by superinfection, but this process depends on production of functional Tat by the superinfecting virus. In a primary cell model of latency in unstimulated CD4 T cells, superinfection also led to latent virus reactivation. Drug-resistant latent viruses were also reactivated following superinfection in Jurkat cells and were able to undergo recombination with the superinfecting virus. Under drug-selective pressure, this generated multidrug-resistant recombinants that were identified by unique restriction digestion band patterns and by population-level sequencing. During conditions of poor drug adherence, treatment interruption or treatment failure, or in drug-impermeable sanctuary sites, reactivation of latent viruses by superinfection or other means could provide for the emergence or spread of replicatively fit viruses in the face of strong selective pressures.
HIV-1 潜伏库是遗传多样性的重要来源,可能会导致潜伏病毒重新激活后病毒进化和多药耐药。这种情况可能是通过潜伏感染细胞的再次感染发生的。我们想知道潜伏病毒在宿主细胞再次感染时是否会被重新激活,如果是这样,它们是否会有助于重组病毒的产生。我们使用潜伏感染的 Jurkat 细胞群体,发现潜伏病毒在再次感染时能被有效激活。通过再次感染导致潜伏病毒重新激活的途径可能包括 gp120-CD4/CXCR4 诱导的信号、Nef 对细胞环境的调节,和/或再次感染时产生的 Tat 的活性。通过使用一系列抗病毒化合物和遗传方法,我们表明 gp120 和 Nef 对于再次感染引起的潜伏病毒重新激活不是必需的,但这一过程依赖于再次感染病毒产生功能性 Tat。在未受刺激的 CD4 T 细胞潜伏的原代细胞模型中,再次感染也导致潜伏病毒重新激活。在 Jurkat 细胞中,耐药潜伏病毒在再次感染后也被重新激活,并能与再次感染的病毒发生重组。在药物选择压力下,这会产生多药耐药重组体,通过独特的限制性消化带模式和群体水平测序来识别。在药物依从性差、治疗中断或治疗失败的情况下,或者在药物渗透不良的避难所部位,再次感染或其他方式重新激活潜伏病毒,可能会导致在强大的选择压力下,适应性强的病毒出现或传播。